Skip to main content

Phase 1 vs Phase 2 — Metabolic Deal Valuation Comparison

Phase 1 Median Upfront
$365M
Total: $2.9B
Phase 2 Median Upfront
$935M
Total: $4.5B
Stage Premium
55%
Phase 2 premium over Phase 1
Phase 1 Royalties
10.7%-20.1%
vs Phase 2: 16.1%-29.5%

Market Analysis

The Phase 1 to Phase 2 transition in metabolic represents a significant value inflection point. Phase 2 deals carry a median total deal value of $4.5B compared to $2.9B at Phase 1, a 55% premium reflecting clinical de-risking. Upfront payments increase from $365M to $935M.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 1 to Phase 2 in metabolic?
Phase 2 metabolic deals command a 55% premium over Phase 1 in total deal value ($4.5B vs $2.9B). Upfronts increase from $365M to $935M, reflecting the de-risking value of clinical progression.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating